PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-41.39%
G&A reduction while CRVO shows 37.03% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
15.06%
Other expenses growth less than half of CRVO's 100.00%. David Dodd would verify if advantage is sustainable.
-38.60%
Operating expenses reduction while CRVO shows 251.41% growth. Joel Greenblatt would examine advantage.
-38.60%
Total costs reduction while CRVO shows 15.98% growth. Joel Greenblatt would examine advantage.
10.73%
Interest expense change of 10.73% while CRVO maintains costs. Bruce Berkowitz would investigate control.
No Data
No Data available this quarter, please select a different quarter.
38.60%
EBITDA growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
38.60%
Operating income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-122.72%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.20%
Tax expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
30.20%
Net income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
30.24%
EPS growth while CRVO declines. John Neff would investigate advantages.
30.24%
Diluted EPS growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.